{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:12:28Z","timestamp":1794856348978,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sepsis is a complex life-threatening clinical condition associated with significant morbidity and mortality. It is usually triggered by an infection, the cellular response to which progresses, involving the innate immune system and leading to a cytokine storm that can provoke death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The device is based on the peptide SET-M33, an antimicrobial molecule with strong antibacterial activity. The peptide was conjugated with a biocompatible agarose matrix via a covalent sulfonic bridge, then encapsulated in a device to insert in a circulation system. Here we describe a medical device that selectively and simultaneously remove the major triggers of the onset and progression of sepsis from the blood of sepsis patients. These include live bacteria and their components, such as lipopolysaccharides (LPS) and lipoteichoic acids (LTA), as well as C reactive protein (CRP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a human serum assay, the device removes 85% of LPS, &gt;80% of LTA, &gt;99% of live Gram-positive and Gram-negative bacteria in serum, and &gt;94% of CRP. In ex vivo animal model in which murine blood spiked with known amounts of LPS, the device removes &gt;80% of the endotoxin. After circulation in the device, the serum shows no significant change in protein content, this confirms that the device does not change the molecular profile of the blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The instrument here described is a prototype with strong potential for clinical applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01187-w","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:05:53Z","timestamp":1761559553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A peptide-based medical device for the selective removal of inflammatory factors from the blood of people with sepsis"],"prefix":"10.1038","volume":"5","author":[{"given":"Giovanni","family":"Cappello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Bocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jlenia","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Falciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3832-8349","authenticated-orcid":false,"given":"Alessandro","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1187_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801\u2013810 (2016).","journal-title":"JAMA"},{"key":"1187_CR2","first-page":"67","volume":"61","author":"I Srzi\u0107","year":"2022","unstructured":"Srzi\u0107, I., Nesek Adam, V. & Tunji\u0107 Pejak, D. Sepsis definition: what\u2019s new in the treatment guidelines. Acta Clin. Croatia 61, 67\u201372 (2022).","journal-title":"Acta Clin. Croatia"},{"key":"1187_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study.Lancet 395, 200\u2013211 (2020).","journal-title":"Lancet"},{"key":"1187_CR4","doi-asserted-by":"publisher","first-page":"e112224","DOI":"10.1371\/journal.pone.0112224","volume":"9","author":"JS Davis","year":"2014","unstructured":"Davis, J. S., He, V., Anstey, N. M. & Condon, J. R. Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 years follow up. PLoS ONE 9, e112224 (2014).","journal-title":"PLoS ONE"},{"key":"1187_CR5","unstructured":"Rubin R., Strayer D. S., Rubin E. Rubin's Pathology: Clinicopathologic Foundations of Medicine VII edn (Wolters Kluwer-Lippincott Williams & Wilkins, 2014)."},{"key":"1187_CR6","unstructured":"Abbas A. K., Lichtman A. H., Pillai S. Cellular and Molecular Immunology X edn (Elsevier, 2021)."},{"key":"1187_CR7","first-page":"938","volume":"31","author":"J Wang","year":"2019","unstructured":"Wang, J., Wang, H., Liu, W., Zhang, D. & Guo, S. Assessment values of procalcitonin, lactic acid, and disease severity scores in patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 31, 938\u2013941 (2019).","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"1187_CR8","first-page":"281","volume":"33","author":"C Hao","year":"2021","unstructured":"Hao, C., Hu, Q., Zhu, L., Xu, H. & Zhang, Y. Combined prognostic value of serum lactic acid, procalcitonin and severity score for short-term prognosis of septic shock patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 33, 281\u2013285 (2021).","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"1187_CR9","first-page":"449","volume":"32","author":"M Zhao","year":"2020","unstructured":"Zhao, M. & Duan, M. Lactic acid, lactate clearance and procalcitonin in assessing the severity and predicting prognosis in sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 32, 449\u2013453 (2020).","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"1187_CR10","doi-asserted-by":"publisher","first-page":"117727192091794","DOI":"10.1177\/1177271920917941","volume":"15","author":"RJ Durrance","year":"2020","unstructured":"Durrance, R. J. et al. Marked elevation in serum procalcitonin levels do not correlate with severity of disease or mortality in hospitalized patients: a retrospective study. Biomark. Insights 15, 1177271920917941 (2020).","journal-title":"Biomark. Insights"},{"key":"1187_CR11","doi-asserted-by":"crossref","unstructured":"Yu, H. et al. Combining procalcitonin with the qSOFA and sepsis mortality prediction. Medicine 98, e15981 (2019).","DOI":"10.1097\/MD.0000000000015981"},{"key":"1187_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14787210.2023.2237192","volume":"21","author":"X Qiu","year":"2023","unstructured":"Qiu, X., Lei, Y. & Zhou, R. SIRS, SOFA, qSOFA, and NEWS in the diagnosis of sepsis and prediction of adverse outcomes: a systematic review and meta-analysis. Expert Rev. Anti-infect. Ther. 21, 891\u2013900 (2023).","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"1187_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1023\/A:1009890031293","volume":"2","author":"E Lin","year":"1998","unstructured":"Lin, E. & Lowry, S. F. The human response to endotoxin. Sepsis 2, 255\u2013262 (1998).","journal-title":"Sepsis"},{"key":"1187_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1369-5274(99)00046-6","volume":"3","author":"B Beutler","year":"2000","unstructured":"Beutler, B. Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr. Opin. Microbiol. 3, 23\u201328 (2000).","journal-title":"Curr. Opin. Microbiol."},{"key":"1187_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-3083.2009.02255.x","volume":"69","author":"A Castellheim","year":"2009","unstructured":"Castellheim, A., Brekke, O.-L., Espevik, T., Harboe, M. & Mollnes, T. E. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand. J. Immunol. 69, 479\u2013491 (2009).","journal-title":"Scand. J. Immunol."},{"key":"1187_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature01326","volume":"420","author":"J Cohen","year":"2002","unstructured":"Cohen, J. The immunopathogenesis of sepsis. Nature. 420, 885\u2013891 (2002).","journal-title":"Nature."},{"key":"1187_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s12272-016-0804-y","volume":"39","author":"SS Kang","year":"2016","unstructured":"Kang, S. S., Sim, J. R., Yun, C. H. & Han, S. H. Lipoteichoic acids as a major virulence factor causing inflammatory responses via Toll-like receptor 2. Arch. Pharm. Res. 39, 1519\u20131529 (2016).","journal-title":"Arch. Pharm. Res."},{"key":"1187_CR18","first-page":"e32405","volume":"14","author":"DA Al-Kader","year":"2022","unstructured":"Al-Kader, D. A. et al. Systematic review on the effects of prompt antibiotic treatment on survival in septic shock and sepsis patients in different hospital settings. Cureus. 14, e32405 (2022).","journal-title":"Cureus."},{"key":"1187_CR19","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/jcmm.13112","volume":"21","author":"XF Shen","year":"2017","unstructured":"Shen, X. F., Cao, K., Jiang, J. P., Guan, W. X. & Du, J. F. Neutrophil dysregulation during sepsis: an overview and update. J. Cell. Mol. Med.21, 1687\u20131697 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"1187_CR20","doi-asserted-by":"publisher","first-page":"628302","DOI":"10.3389\/fmed.2021.628302","volume":"8","author":"D Jarczak","year":"2021","unstructured":"Jarczak, D., Kluge, S. & Nierhaus, A. Sepsis-pathophysiology and therapeutic concepts. Front. Med. 8, 628302 (2021).","journal-title":"Front. Med."},{"key":"1187_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2023","unstructured":"Martin, G. S., Mannino, D. M., Eaton, S. & Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl. J. Med. 348, 1546\u20131554 (2023).","journal-title":"New Engl. J. Med."},{"key":"1187_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0891-5520(05)70082-9","volume":"13","author":"S Sriskandan","year":"1999","unstructured":"Sriskandan, S. & Cohen, J. Gram-positive sepsis. Mechanisms and differences from Gram-negative sepsis. Infect. Dis. Clin. N. Am. 13, 397\u2013412 (1999).","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"1187_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1378\/chest.99.1.169","volume":"99","author":"RL Danner","year":"1991","unstructured":"Danner, R. L. et al. Endotoxemia in human septic shock. Chest. 99, 169\u2013175 (1991).","journal-title":"Chest."},{"key":"1187_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s001340051201","volume":"26","author":"C Venet","year":"2000","unstructured":"Venet, C. et al. Endotoxaemia in patients with severe sepsis or septic shock. Intensive Care Med. 26, 538\u2013544 (2000).","journal-title":"Intensive Care Med."},{"key":"1187_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/09680519030090050201","volume":"9","author":"JC Hurley","year":"2003","unstructured":"Hurley, J. C. Endotoxemia and Gram-negative bacteremia as predictors of outcome in sepsis: a meta-analysis using ROC curves. J. Endotoxin Res. 9, 271\u2013279 (2003).","journal-title":"J. Endotoxin Res."},{"key":"1187_CR26","doi-asserted-by":"crossref","unstructured":"Esteban, E., Ferrer, R., Alsina, L. & Artigas, A. Immunomodulation in sepsis: the role of endotoxin removal by Polymyxin B-immobilized cartridge. Mediat. Inflamm. 2013, 507539 (2013).","DOI":"10.1155\/2013\/507539"},{"key":"1187_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-018-0177-2","volume":"6","author":"B Malard","year":"2018","unstructured":"Malard, B., Lambert, C. & Kellum, J. A. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med. Exp. 6, 12 (2018).","journal-title":"Intensive Care Med. Exp."},{"key":"1187_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000527355","volume":"200","author":"M Cecchi","year":"2023","unstructured":"Cecchi, M., Ulsamer, A. & Villa, G. Oxiris membrane in sepsis and multiple organ failure. Contrib. Nephrol. 200, 55\u201365 (2023).","journal-title":"Contrib. Nephrol."},{"key":"1187_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-3-030-16373-0_19","volume":"1145","author":"T Tani","year":"2019","unstructured":"Tani, T., Shimizu, T., Tani, M., Shoji, H. & Endo, Y. Anti-endotoxin properties of Polymyxin B-immobilized fibers. Adv. Exp. Med. Biol. 1145, 321\u2013341 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1187_CR30","first-page":"CD008075","volume":"1","author":"EM Borthwick","year":"2017","unstructured":"Borthwick, E. M. et al. High-volume haemofiltration for sepsis in adults. Cochrane Database Syst. Rev. 1, CD008075 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1187_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5492\/wjccm.v10.i1.22","volume":"10","author":"R Paul","year":"2021","unstructured":"Paul, R. et al. Multicentered prospective investigator-initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb\u00ae) in patients with sepsis and septic shock. World J. Crit. Care Med. 10, 22\u201334 (2021).","journal-title":"World J. Crit. Care Med."},{"key":"1187_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5935\/2965-2774.20230289-en","volume":"35","author":"JJC Salda\u00f1a-Gastulo","year":"2023","unstructured":"Salda\u00f1a-Gastulo, J. J. C., Llamas-Barbar\u00e1n, M., Coronel-Chucos, L. G. & Hurtado-Roca, Y. Cytokine hemoadsorption with CytoSorb\u00ae in patients with sepsis: a systematic review and meta-analysis. Crit. Care Sci. 35, 217\u2013225 (2023).","journal-title":"Crit. Care Sci."},{"key":"1187_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00005-015-0348-8","volume":"63","author":"B Adamik","year":"2015","unstructured":"Adamik, B., Zielinski, S., Smiechowicz, J. & K\u00fcbler, A. Endotoxin elimination in patients with septic shock: an observation study. Arch. Immunol. Ther. Exp. 63, 475\u2013483 (2015).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"1187_CR34","doi-asserted-by":"publisher","first-page":"672260","DOI":"10.3389\/fped.2021.672260","volume":"9","author":"V Sazonov","year":"2021","unstructured":"Sazonov, V. et al. Case Series: Efficacy and safety of hemoadsorption with HA 330 adsorber in septic pediatric patients with cancer. Front. Pediatr. 9, 672260 (2021).","journal-title":"Front. Pediatr."},{"key":"1187_CR35","first-page":"582","volume":"27","author":"Y Feng","year":"2021","unstructured":"Feng, Y., Peng, J. & Peng, Z. Blood purification in sepsis and systemic inflammation. Curr. Opin.Clin. Care 27, 582\u2013586 (2021).","journal-title":"Curr. Opin.Clin. Care"},{"key":"1187_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000333837","volume":"33","author":"PM Honor\u00e9","year":"2012","unstructured":"Honor\u00e9, P. M. et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif. 33, 44\u201351 (2012).","journal-title":"Blood Purif."},{"key":"1187_CR37","doi-asserted-by":"publisher","first-page":"e003536","DOI":"10.1136\/bmjopen-2013-003536","volume":"4","author":"S Livigni","year":"2014","unstructured":"Livigni, S. et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4, e003536 (2014).","journal-title":"BMJ Open"},{"key":"1187_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1096\/fj.09-145474","volume":"24","author":"A Pini","year":"2010","unstructured":"Pini, A. et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J. 24, 1015\u20131022 (2010).","journal-title":"FASEB J."},{"key":"1187_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep26077","volume":"6","author":"J Brunetti","year":"2016","unstructured":"Brunetti, J. et al. In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Sci. Rep. 6, 26077 (2016a).","journal-title":"Sci. Rep."},{"key":"1187_CR40","doi-asserted-by":"publisher","first-page":"7967","DOI":"10.3390\/ijms24097967","volume":"24","author":"L Cresti","year":"2023","unstructured":"Cresti, L. et al. In Vivo efficacy and toxicity of an antimicrobial peptide in a model of endotoxin-induced pulmonary inflammation. Int. J. Mol. Sci. 24, 7967 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1187_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23841-2","volume":"12","author":"L Cresti","year":"2022","unstructured":"Cresti, L. et al. Safety evaluations of a synthetic antimicrobial peptide administered intravenously in rats and dogs. Sci. Rep. 12, 19294 (2022a).","journal-title":"Sci. Rep."},{"key":"1187_CR42","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.bbamem.2017.06.001","volume":"1859","author":"H Van der Weide","year":"2017","unstructured":"Van der Weide, H. et al. Investigations into the killing activity of an antimicrobial peptide active against extensively antibiotic-resistant K. pneumoniae and P. aeruginosa. Biochim. Biophys. Acta 1859, 1796\u20131804 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"1187_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1096\/fj.201901896RR","volume":"34","author":"L Quercini","year":"2020","unstructured":"Quercini, L. et al. An antimicrobial molecule mitigates signs of sepsis in vivo and eradicates infections from lung tissue. FASEB J. 34, 192\u2013207 (2020).","journal-title":"FASEB J."},{"key":"1187_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.chom.2022.12.003","volume":"31","author":"S Dyzenhaus","year":"2023","unstructured":"Dyzenhaus, S. et al. MRSA lineage USA300 isolated from bloodstream infections exhibit altered virulence regulation. Cell Host Microbe 31, 228\u2013242.e8 (2023).","journal-title":"Cell Host Microbe"},{"key":"1187_CR45","doi-asserted-by":"publisher","first-page":"e46259","DOI":"10.1371\/journal.pone.0046259","volume":"7","author":"C Falciani","year":"2012","unstructured":"Falciani, C. et al. Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to Gram-positive bacterial pathogens. PLoS ONE 7, e46259 (2012).","journal-title":"PLoS ONE"},{"key":"1187_CR46","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston, N. R. & Ashworth, J. J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 9, 754 (2018).","journal-title":"Front. Immunol."},{"key":"1187_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04044-7","volume":"26","author":"G Eden","year":"2022","unstructured":"Eden, G. et al. Safety and efficacy of the Seraph\u00ae 100 Microbind\u00ae Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit. Care 26, 181 (2022).","journal-title":"Crit. Care"},{"key":"1187_CR48","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1046\/j.1526-0968.2003.00005.x","volume":"7","author":"H Shoji","year":"2003","unstructured":"Shoji, H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther. Apher. Dial. 7, 108\u2013114 (2003).","journal-title":"Ther. Apher. Dial."},{"key":"1187_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1473-0502(03)00100-9","volume":"29","author":"KH Staubach","year":"2003","unstructured":"Staubach, K. H., Boehme, M., Zimmermann, M. & Otto, V. A new endotoxin adsorption device in Gram-negative sepsis: use of immobilized albumin with the MATISSE adsorber. Transfus. Apher. Sci. 29, 93\u201398 (2003).","journal-title":"Transfus. Apher. Sci."},{"key":"1187_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/SHK.0000000000001503","volume":"54","author":"M Lipcsey","year":"2020","unstructured":"Lipcsey, M. et al. Endotoxin removal in septic shock with the Alteco LPS Adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial\u2014the asset study. Shock 54, 224\u2013231 (2020).","journal-title":"Shock"},{"key":"1187_CR51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5301\/ijao.5000429","volume":"38","author":"B Hinz","year":"2015","unstructured":"Hinz, B. et al. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int. J. Artif. Organs 38, 461\u2013464 (2015).","journal-title":"Int. J. Artif. Organs"},{"key":"1187_CR52","doi-asserted-by":"publisher","first-page":"e0220444","DOI":"10.1371\/journal.pone.0220444","volume":"14","author":"ME Broman","year":"2019","unstructured":"Broman, M. E., Hansson, F., Vincent, J. L. & Bodelsson, M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE 14, e0220444 (2019).","journal-title":"PLoS ONE"},{"key":"1187_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/pharmaceutics15010003","volume":"15","author":"L Cresti","year":"2022","unstructured":"Cresti, L. et al. Inhalable polymeric nanoparticles for pulmonary delivery of antimicrobial peptide SET-M33: antibacterial activity and toxicity in vitro and in vivo. Pharmaceutics 15, 3 (2022b).","journal-title":"Pharmaceutics"},{"key":"1187_CR54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2174\/138920308785915227","volume":"9","author":"A Pini","year":"2008","unstructured":"Pini, A., Falciani, C. & Bracci, L. Branched peptides as therapeutics. Curr. Protein Peptide Sci. 9, 468\u2013477 (2008).","journal-title":"Curr. Protein Peptide Sci."},{"key":"1187_CR55","doi-asserted-by":"publisher","first-page":"25742","DOI":"10.1074\/jbc.M116.750257","volume":"291","author":"J Brunetti","year":"2016","unstructured":"Brunetti, J. et al. Immunomodulatory and anti-inflammatory activity in vitro and in vivo of a novel antimicrobial candidate. J. Biol. Chem. 291, 25742\u201325748 (2016b).","journal-title":"J. Biol. Chem."},{"key":"1187_CR56","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.3390\/ijms25094870","volume":"25","author":"L Cresti","year":"2024","unstructured":"Cresti, L., Cappello, G. & Pini, A. Antimicrobial peptides towards clinical application\u2014a long history to be concluded. Int. J. Mol. Sci. 25, 4870 (2024). 29.","journal-title":"Int. J. Mol. Sci."},{"key":"1187_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.imbio.2008.02.005","volume":"213","author":"U Z\u00e4hringer","year":"2008","unstructured":"Z\u00e4hringer, U., Lindnera, B., Inamuraa, S., Heineb, H. & Alexandera, C. TLR2\u2014promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology. 213, 205\u2013224 (2008).","journal-title":"Immunobiology."},{"key":"1187_CR58","doi-asserted-by":"crossref","unstructured":"Martinez De Tejada, G. et al. Lipoproteins\/peptides are sepsis inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. Sci. Rep. 5, 14292 (2015).","DOI":"10.1038\/srep14292"},{"key":"1187_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fphar.2012.00056","volume":"3","author":"C Rockel","year":"2012","unstructured":"Rockel, C. & Hartung, T. Systematic review of membrane components of Gram positive bacteria responsible as pyrogens for inducing human monocyte\/macrophage cytokine release. Front. Pharmacol. 3, 56 (2012).","journal-title":"Front. Pharmacol."},{"key":"1187_CR60","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.4049\/jimmunol.177.5.3162","volume":"177","author":"M Hashimoto","year":"2006","unstructured":"Hashimoto, M. et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177, 3162\u20133169 (2006).","journal-title":"J. Immunol."},{"key":"1187_CR61","doi-asserted-by":"publisher","first-page":"15654","DOI":"10.1074\/jbc.M112.446963","volume":"288","author":"N Gisch","year":"2013","unstructured":"Gisch, N. et al. Structural reevaluation of Streptococcus pneumonia lipoteichoic acid and new Insights into its immunostimulatory potency. J. Biol. Chem. 288, 15654\u201315667 (2013).","journal-title":"J. Biol. Chem."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01187-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01187-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01187-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:05:57Z","timestamp":1761559557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01187-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01187-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: the peptide SET-M33 is covered by patents owned by SetLance srl or by the University of Siena and licensed to SetLance srl. A.P., C.F., and L.B. are partners of SetLance. The rest of the authors declare that they have no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing-interests"}}],"article-number":"436"}}